Belvarafenib TFA
Based on 6 publication(s) in Google Scholar
Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
For research use only. We do not sell to patients.
- CAS No.: 2443966-84-3
- Formula: C25H17ClF4N6O3S
- Molecular Weight:592.95
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Belvarafenib TFA
More-
RT-PCR
-
WB
-
Apoptosis Analysis
-
IF
-
In Vivo Efficacy Study
Biological Activity
IC50: 56 nM(B-RAF), 7 nM(B-RAFv600E), 5 nM(C-RAF)[1].
Belvarafenib (Example 116) is a potent and pan RAF inhibitor with antineoplastic activity. The IC50 values of Belvarafenib are 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. It also shows high inhibitory activity for FMS, DDR1 and DDR2 kinases, with IC50s of 10 nM, 23 nM and 44 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2443966-84-3
-
Appearance Solid
-
Molecular Weight 592.95
-
Formula C25H17ClF4N6O3S
-
Color White to off-white
-
SMILES
O=C(C(C1=NC=N2)=CSC1=C2N)NC(C3=C4C(NC(C=CC=C5Cl)=C5F)=NC=C3)=C(C=C4)C.OC(C(F)(F)F)=O
-
Synonyms
HM95573 TFA; GDC-5573 TFA; RG6185 TFA
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathway. [Abstract]2026 May 6;17(1):600. PMID: 42091854
Belvarafenib TFA purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2026 May 6;17(1):600. [Abstract]
Fold change of MTHFD2 transcripts following indicated treatment in WM3406 cells (left) and MeWo cells (right) treated with INK128, Cobimetinib and Belvarafenib (25 nM).
Belvarafenib TFA purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2026 May 6;17(1):600. [Abstract]
Western blot analysis of the indicated proteins in WM3406 (left) and MeWo (right) cells with ATF4 knockdown or Belvarafenib (25 nM) plus Cobimetinib treatment.
Belvarafenib TFA purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2026 May 6;17(1):600. [Abstract]
Percent apoptosis detected in DMSO- or Belvarafenib plus Cobimetinib- or Belvarafenib (25 nM) plus Cobimetinib plus nucleosides-treated WM3406 or MeWo cells.
Belvarafenib TFA purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2026 May 6;17(1):600. [Abstract]
Representative images of WM3406 and MeWo cells following Belvarafenib plus Cobimetinib- or Belvarafenib (25 nM) plus Cobimetinib plus nucleosides-treated for 18 h and processed for γH2AX (green) immunofluorescence.
Belvarafenib TFA purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2026 May 6;17(1):600. [Abstract]
Tumor growth curve comparing MaNRAS1007 melanomas grown on C57BL/6N host mice with or without Belvarafenib (5 mg/kg, i.g.) plus Cobimetinib treatments.
-
Proc Natl Acad Sci U S A
2023 Oct 10;120(41):e2308635120. PMID: 37782788 -
J Invest Dermatol
Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma. [Abstract]2025 Apr;145(4):979-984.e5. PMID: 39357785 -
-
-
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. WO 2013/100632 A1.
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)